ATXI Avenue Therapeutics Inc

Item 1.

(a) Name of Issuer

Avenue Therapeutics, Inc. (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices

2 Gansevoort Street, 9th Floor

New York, New York 10014

Item 2.

(a) Name of Person Filing

(b) Address of Principal Business Office or, if none, Residence

(c) Citizenship

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

(d) Title of Class of Securities

Common Stock, $0.0001 par value per share, of the Issuer (the “Common Stock”).

(e) CUSIP Number

05360L205

Not applicable.

(a) and (b):

(i) Immediately following the consummation of the underwritten public offering by the Issuer on October 11, 2022 (the “Offering”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on October 11, 2022), each of the Reporting Persons may have been deemed to have beneficial ownership of 272,700 shares of Common Stock held by Intracoastal, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 6.6% of the Common Stock, based on 4,127,717 shares of Common Stock outstanding following the consummation of the Offering as reported by the Issuer. The foregoing excludes 272,700 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”) because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 545,400 shares of Common Stock.

(ii) As of the close of business on October 14, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 216,790 shares of Common Stock issuable upon exercise of the Intracoastal Warrant, and all such shares of Common Stock represented beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 4,127,717 shares of Common Stock outstanding following the consummation of the Offering as reported by the Issuer, plus (2) 216,790 shares of Common Stock issuable upon exercise of the Intracoastal Warrant. The foregoing excludes 55,910 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 272,700 shares of Common Stock

(c) Number of shares as to which each Reporting Person has:

(i) Sole power to vote or to direct the vote:    0    .

(ii) Shared power to vote or to direct the vote:    216,790    .

(iii) Sole power to dispose or to direct the disposition of    0    .

(iv) Shared power to dispose or to direct the disposition of    216,790    .

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Page 8 of 8